Alkami Technology rejected a sale after months of pressure from activist investor Jana Partners, saying its board unanimously concluded that executing the company’s long-range strategy as an independent public company would best serve shareholders. Jana bought its stake in December and increased it to more than 10% in June; it owned more than 6.74 million shares at the end of the second quarter and had urged Alkami to explore a sale amid interest from multiple potential buyers. Alkami reaffirmed full-year guidance for revenue of $528 million to $531 million and adjusted EBITDA of $96 million to $98 million. Shares fell 19% after the strategic review decision and later reached a 52-week and three-year low of $13.76, reducing the value of Jana’s position from about $122.3 million at the end of the second quarter to $93.3 million. Jana has not said whether it will sell its stake or seek changes to Alkami’s board. The existing topic also recorded a separate roughly 74% plunge in Jaguar Health shares on September 23 and mentioned Cullinan without further details.